Revolution Medicines’ Promising RAS+ NSCLC Market Position and Drug Efficacy Justify Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on RVMD stock, giving a Buy rating today.

Marc Frahm has given his Buy rating due to a combination of factors including Revolution Medicines’ promising data updates and strategic positioning in the RAS+ NSCLC market. The company’s recent Q1 results highlighted the potential of their drugs, daraxonrasib and elironrasib, to be effectively combined with PD-1 inhibitors and chemotherapy, showing significant improvements in overall response rates.
Furthermore, the combinability and efficacy of these treatments in the first-line setting for RAS+ NSCLC, which is a substantial market opportunity, underscore the potential for Revolution Medicines to lead in this space. The well-tolerated nature of these combinations and the potential for a differentiated chemo-free regimen add to the attractiveness of the stock. These developments, along with the anticipated pivotal trials set for 2026, reinforce the positive outlook for Revolution Medicines, justifying the Buy rating.

In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $78.00 price target.